Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy.

作者: Roberto Labianca , Maria Adelaide Pessi , Giuseppina Zamparelli

DOI: 10.2165/00003495-199753040-00005

关键词:

摘要: Colorectal carcinoma is one of the most common cancers in Western countries (yearly incidence rate 1: 3000), and represents, after lung cancer, second leading cause deaths due to cancer. During past decades, knowledge about this has considerably increased, but little progress been made improvement patient survival. At least 40% patients with colorectal cancer will have metastases sometime during course their illness.

参考文章(66)
Survival after postoperative combination treatment of rectal cancer. The New England Journal of Medicine. ,vol. 315, pp. 1294- 1295 ,(1986) , 10.1056/NEJM198611133152014
U. Metzger, Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference. European Journal of Cancer and Clinical Oncology. ,vol. 26, pp. 753- 755 ,(1990) , 10.1016/0277-5379(90)90136-H
H C Hoover, J S Brandhorst, L C Peters, M G Surdyke, Y Takeshita, J Madariaga, L R Muenz, M G Hanna, Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. Journal of Clinical Oncology. ,vol. 11, pp. 390- 399 ,(1993) , 10.1200/JCO.1993.11.3.390
N Wolmark, H Rockette, D L Wickerham, B Fisher, C Redmond, E R Fisher, M Potvin, R J Davies, J Jones, A Robidoux, Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. Journal of Clinical Oncology. ,vol. 8, pp. 1466- 1475 ,(1990) , 10.1200/JCO.1990.8.9.1466
C G Moertel, T R Fleming, J S Macdonald, D G Haller, J A Laurie, C M Tangen, J S Ungerleider, W A Emerson, D C Tormey, J H Glick, Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2936- 2943 ,(1995) , 10.1200/JCO.1995.13.12.2936
M A Poon, M J O'Connell, C G Moertel, H S Wieand, S A Cullinan, L K Everson, J E Krook, J A Mailliard, J A Laurie, L K Tschetter, Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. Journal of Clinical Oncology. ,vol. 7, pp. 1407- 1418 ,(1989) , 10.1200/JCO.1989.7.10.1407
D Machover, E Goldschmidt, P Chollet, G Metzger, J Zittoun, J Marquet, J M Vandenbulcke, J L Misset, L Schwarzenberg, J B Fourtillan, Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. Journal of Clinical Oncology. ,vol. 4, pp. 685- 696 ,(1986) , 10.1200/JCO.1986.4.5.685
R. Labianca, G. Pancera, E. Aitini, S. Barni, A. Beretta, G.D. Beretta, B. Cesana, G. Comella, L. Cozzaglio, M. Cristoni, P. Spagnolli, L. Frontini, O. Gottardi, G. Martignoni, R. Scapaticci, F. Smerieri, M. Vinci, A. Zadro, A. Zaniboni, G. Luporini, Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). Annals of Oncology. ,vol. 2, pp. 673- 679 ,(1991) , 10.1093/OXFORDJOURNALS.ANNONC.A058047
T R Buroker, M J O'Connell, H S Wieand, J E Krook, J B Gerstner, J A Mailliard, P L Schaefer, R Levitt, C G Kardinal, D H Gesme, Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Journal of Clinical Oncology. ,vol. 12, pp. 14- 20 ,(1994) , 10.1200/JCO.1994.12.1.14